Profile data is unavailable for this security.
About the company
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. It has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-102, RT-105, RT-111 and RT-110. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC, which is intended to enable delivery of drug payloads up to 200uL in liquid form with high bioavailability.
- Revenue in USD (TTM)0.00
- Net income in USD-33.08m
- Incorporated2021
- Employees140.00
- LocationRani Therapeutics Holdings Inc2051 Ringwood AvenueSAN JOSE 95131United StatesUSA
- Phone+1 (408) 457-3700
- Fax+1 (302) 655-5049
- Websitehttps://www.ranitherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chromadex Corp | 83.17m | -3.53m | 249.28m | 106.00 | -- | 8.57 | -- | 3.00 | -0.047 | -0.047 | 1.11 | 0.3852 | 1.54 | 2.66 | 10.01 | 784,594.30 | -6.54 | -42.11 | -10.08 | -65.14 | 60.98 | 59.68 | -4.24 | -30.64 | 1.88 | -- | 0.0007 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
| Century Therapeutics Inc | 1.37m | -133.47m | 249.37m | 152.00 | -- | 1.10 | -- | 182.02 | -2.22 | -2.22 | 0.0227 | 2.74 | 0.0034 | -- | -- | 9,013.16 | -33.17 | -- | -35.08 | -- | -- | -- | -9,742.41 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
| ESSA Pharma Inc | 0.00 | -27.73m | 252.16m | 50.00 | -- | 1.89 | -- | -- | -0.6282 | -0.6282 | 0.00 | 3.01 | 0.00 | -- | -- | 0.00 | -18.71 | -23.01 | -19.12 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
| Codexis Inc | 74.23m | -65.13m | 254.71m | 174.00 | -- | 3.21 | -- | 3.43 | -0.9412 | -0.9412 | 1.07 | 1.12 | 0.4039 | 5.92 | 4.34 | 426,632.20 | -35.43 | -17.13 | -43.38 | -20.23 | 82.29 | 77.29 | -87.73 | -37.04 | 3.63 | -- | 0.2617 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
| XBiotech Inc | 0.00 | -30.74m | 256.74m | 92.00 | -- | 1.23 | -- | -- | -1.01 | -1.01 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | -13.08 | 31.88 | -13.68 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0456 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
| Enanta Pharmaceuticals Inc | 72.88m | -131.74m | 256.91m | 145.00 | -- | 1.55 | -- | 3.53 | -6.25 | -6.25 | 3.46 | 7.84 | 0.197 | -- | 5.70 | 502,627.60 | -35.60 | -14.56 | -40.33 | -15.62 | -- | -- | -180.75 | -54.96 | -- | -- | 0.0085 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
| Monte Rosa Therapeutics Inc | 1.06m | -135.28m | 261.69m | 133.00 | -- | 1.71 | -- | 245.95 | -2.53 | -2.53 | 0.0197 | 3.04 | 0.0037 | -- | 0.768 | 8,000.00 | -46.99 | -- | -52.64 | -- | -- | -- | -12,714.47 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
| Metagenomi Inc | 44.76m | -68.26m | 262.31m | 236.00 | -- | -- | -- | 5.86 | -1.82 | -1.82 | 1.19 | 5.73 | -- | -- | -- | 189,644.10 | -- | -- | -- | -- | -- | -- | -152.50 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| Sanara Medtech Inc | 64.99m | -4.30m | 263.08m | 107.00 | -- | 5.81 | -- | 4.05 | -0.5219 | -0.5219 | 7.85 | 5.25 | 0.9635 | 1.90 | 8.37 | 607,381.70 | -6.58 | -17.73 | -8.17 | -22.07 | 87.92 | 88.08 | -6.83 | -17.13 | 1.04 | -18.75 | 0.1786 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -33.08m | 263.19m | 140.00 | -- | 34.03 | -- | -- | -1.29 | -1.29 | 0.00 | 0.1534 | 0.00 | -- | -- | 0.00 | -87.80 | -- | -140.92 | -- | -- | -- | -- | -- | -- | -28.75 | 0.6695 | -- | -- | -- | -11.06 | -- | -- | -- |
| Zura Bio Ltd | 0.00 | -60.18m | 263.74m | 14.00 | -- | 4.32 | -- | -- | -1.63 | -1.63 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -86.77 | -- | -127.21 | -- | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -2,050.99 | -- | -- | -- |
| TriSalus Life Sciences Inc | 18.51m | -63.28m | 267.52m | 112.00 | -- | -- | -- | 14.45 | -1.84 | -1.84 | 0.5991 | -0.982 | 0.7758 | 1.30 | 7.24 | 165,267.90 | -247.43 | -- | -17,440.77 | -- | 85.93 | -- | -318.95 | -- | 1.25 | -13.69 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| MacroGenics Inc | 43.36m | -23.24m | 273.08m | 339.00 | -- | 2.57 | -- | 6.30 | -0.3754 | -0.3754 | 0.6969 | 1.70 | 0.1465 | 5.13 | 2.00 | 127,896.80 | -7.85 | -37.76 | -9.48 | -45.53 | 84.28 | -- | -53.60 | -133.96 | 3.61 | -96.21 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
| Medifast Inc | 897.81m | 67.76m | 273.43m | 634.00 | 4.03 | 1.30 | 3.37 | 0.3046 | 6.20 | 6.20 | 82.15 | 19.29 | 2.88 | 3.37 | -- | 1,416,106.00 | 21.71 | 41.25 | 32.62 | 69.38 | 73.15 | 73.20 | 7.55 | 10.06 | 2.25 | -- | 0.00 | 49.18 | -32.94 | 16.43 | -30.75 | 12.25 | 5.59 | 17.72 |
| Black Diamond Therapeutics Inc | 0.00 | -79.79m | 273.95m | 54.00 | -- | 2.45 | -- | -- | -1.70 | -1.70 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -57.38 | -40.29 | -64.24 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
| Acrivon Therapeutics Inc | 0.00 | -64.12m | 274.48m | 58.00 | -- | 1.86 | -- | -- | -2.88 | -2.88 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -44.11 | -- | -46.46 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
Data as of May 17 2024. Currency figures normalised to Rani Therapeutics Holdings Inc's reporting currency: US Dollar USD
7.05%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 681.40k | 2.59% |
| USAA Investment Services Co.as of 31 Mar 2024 | 481.30k | 1.83% |
| Stifel Nicolaus & Co., Inc. (Investment Management)as of 31 Mar 2024 | 132.43k | 0.50% |
| Geode Capital Management LLCas of 31 Mar 2024 | 130.91k | 0.50% |
| Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 31 Mar 2024 | 122.65k | 0.47% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 70.30k | 0.27% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 63.58k | 0.24% |
| Avenue Capital Management II LPas of 31 Mar 2024 | 62.89k | 0.24% |
| Luther King Capital Management Corp.as of 31 Mar 2024 | 56.13k | 0.21% |
| Bridgeway Capital Management LLCas of 31 Mar 2024 | 51.50k | 0.20% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
